Lupin loses key patent battle; Myrbetriq® dispute continues

Lupin is embroiled in an ongoing legal battle with Astellas Pharma Inc. over its generic version of Myrbetriq®. On April 15, 2025, the United States District Court for the District of Delaware ruled in favor of Astellas Pharma, upholding the validity of its U.S. Patent No. 10,842,780. While the court's recent decision concerns the validity of the patent, it deferred rulings on whether Lupin's products infringe the '780 patent, potential damages, and any additional invalidity arguments. These matters will be addressed at a consolidated jury trial scheduled for 2026. Despite the unfavorable ruling, Lupin believes it has a strong case and is evaluating further legal action. At present, Lupin does not anticipate material financial implications stemming from the recent court order and will continue to defend its position vigorously.